Bayer's Two Clocks: An FDA Approval, a 3 Billion Euro Deal, and One Judge in Missouri

FDA accelerated approval for Bayer's Hyrnuo lung cancer drug and a Japan filing for Kerendia meet ongoing Roundup settlement uncertainty.

Bayer's oncology pipeline delivered the kind of headline the company has been starved of for years. On September 9, the US Food and Drug Administration granted accelerated approval to Hyrnuo, a drug whose active ingredient, sevabertinib, is now cleared as a first-line option for adults with locally advanced or metastatic non-squamous non-small cell lung cancer carrying specific activating mutations in the HER2 tyrosine kinase domain. In the SOHO-01 trial, the therapy produced an objective response rate of 75 percent among previously untreated patients.

That result is more than a scientific footnote. It is evidence that Bayer's research spending is producing commercial assets, and it arrives alongside a second regulatory milestone: a filing submitted roughly two weeks ago for Kerendia in Japan, where the company is seeking approval for the treatment of non-diabetic chronic kidney disease.

Yet the laboratory momentum stands in sharp relief against the legal machinery still grinding in the United States. The company's shares slipped 1.1 percent in the latest session to EUR 48.69, and stood at EUR 48.79 in pre-market trading, down 1.2 percent since last Monday's court hearing on the Roundup settlement. Investors are left to weigh the promise of new molecules against the financial uncertainty of litigation that has shadowed Bayer for years.

What the Balance Sheet Must Prove

The central question is whether Bayer can generate enough cash from its own operations to absorb future settlement and litigation costs without eroding its asset base — while still funding new medicines and servicing existing obligations.

Recent quarterly figures suggest the day-to-day business can carry part of that load. In the second quarter of 2026, Bayer posted revenue of EUR 10.87 billion, with adjusted earnings before interest, taxes, depreciation and amortization rising 1.9 percent to EUR 2.14 billion. That operating result beat analyst expectations, with the Crop Science agricultural division serving as the sole growth engine while other units stalled. Management subsequently reaffirmed its currency-adjusted full-year guidance, targeting adjusted EBITDA of EUR 9.6 billion to EUR 10.1 billion for 2026.

The liability side of the ledger matters just as much to creditors and shareholders. Under an agreed partnership with private equity firm Apollo, Bayer will receive EUR 3.0 billion in equity through a minority stake in a vehicle housing its long-acting contraceptive business. The transaction prompted the company to lower its net financial debt target to between EUR 29 billion and EUR 30 billion, down from a previous range of EUR 32 billion to EUR 33 billion. Completion is slated for the third quarter of 2026 and forms the financial bedrock for future pipeline investment.

Judith Hartmann has overseen capital allocation as chief financial officer since the end of May, succeeding Wolfgang Nickl. Her mandate is straightforward and unforgiving: stabilize the balance sheet. Without strict financial discipline, the balancing act between legacy liabilities and future investment becomes unmanageable.

The Case for a Clean Break

In the optimistic reading, Bayer secures a legal breakthrough that clears the way for a revaluation. The negotiated collective settlement calls for annual payments that decline over a period of up to 21 years, with a maximum total of USD 7.25 billion. Should the court grant final approval, the company would gain a predictable timeline and a defined financial envelope, largely neutralizing the unpredictable threat of rolling waves of litigation and returning strategic latitude to management.

Additional support came from the US Supreme Court's June 26 ruling in Monsanto v. Durnell, in which the justices held that state-level failure-to-warn claims are preempted by federal law as long as the EPA does not require warning labels. The court backed that position by a 7-2 margin, and on August 27 the Eighth Circuit Court of Appeals rejected a related challenge. Against that backdrop, Barclays raised its price target in September from EUR 60 to EUR 70 while keeping a Buy rating on the stock.

The pipeline offers further optionality. The May 2026 agreement to acquire Perfuse Therapeutics for up to USD 2.45 billion — comprising a USD 300 million upfront payment plus success-based milestone payments — strengthens development efforts in ophthalmology. Should the glyphosate settlement win final approval, it would draw a legal line under a large share of the US claims. In such an environment, Bayer could push net debt below EUR 30 billion as planned, a move that would meaningfully narrow the valuation discount to European chemical and pharmaceutical peers.

Where the Plan Could Stall

The principal risk is delay or obstruction of those very breakthroughs. If the court in Missouri imposes additional conditions on final approval of the settlement or permits new appeals, legal uncertainty remains a permanent companion — consuming management attention and keeping the stock's risk premium elevated.

On the operating side, the lung cancer segment carries commercial risk despite the FDA green light, since new therapies must first establish themselves against existing standards of care in clinical practice. The Japanese approval process for Kerendia, filed roughly two weeks ago, is no formality either; it remains subject to regulatory review.

A delayed closing of the EUR 3.0 billion Apollo transaction, expected this quarter, would push the projected reduction in net financial debt to EUR 29-30 billion further out and leave interest expense weighing on group earnings longer than planned.

Even a confirmed settlement brings no instant relief. The agreed payments tie up liquidity for more than two decades — capital unavailable for proprietary research or targeted portfolio additions. The company would remain financially constrained for years.

That mix is also capping the share price. The stock is up 32 percent year to date but still trades below its 52-week high of EUR 53.86. Market participants remain in wait-and-see mode until the legal risks are formally resolved.

What to Watch Next

The near-term verdict belongs to whichever force prevails first. As long as operating profitability holds steady and full-year targets are met, the recovery scenario retains its validity. If the planned settlement collapses in court, legal headwinds would swiftly extinguish hopes of a rapid revaluation.

Two catalysts now dominate the calendar: the pending ruling from the Missouri court on final approval of the glyphosate settlement, and confirmation that the Apollo transaction reaches financial closing before the quarter ends. Until those two clocks stop ticking, Bayer remains a stock caught between operational promise and a legal examination it cannot skip.